NASDAQ:PBYI - Puma Biotechnology Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $10.00
  • Forecasted Upside: 316.67 %
  • Number of Analysts: 4
  • Breakdown:
  • 1 Sell Ratings
  • 1 Hold Ratings
  • 2 Buy Ratings
  • 0 Strong Buy Ratings
▼ -0.12 (-4.76%)

This chart shows the closing price for PBYI by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Puma Biotechnology Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for PBYI and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for PBYI

Analyst Price Target is $10.00
▲ +316.67% Upside Potential
This price target is based on 4 analysts offering 12 month price targets for Puma Biotechnology in the last 3 months. The average price target is $10.00, with a high forecast of $15.00 and a low forecast of $6.00. The average price target represents a 316.67% upside from the last price of $2.40.

This chart shows the closing price for PBYI for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Hold

The current consensus among 4 investment analysts is to hold stock in Puma Biotechnology. This rating has held steady since July 2021, when it changed from a Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 2 buy ratings
  • 5 hold ratings
  • 4 sell ratings
  • 0 strong buy ratings
  • 2 buy ratings
  • 5 hold ratings
  • 2 sell ratings
  • 0 strong buy ratings
  • 2 buy ratings
  • 4 hold ratings
  • 1 sell ratings
  • 0 strong buy ratings
  • 2 buy ratings
  • 3 hold ratings
  • 1 sell ratings
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 1 sell ratings
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 1 sell ratings
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 1 sell ratings

Latest Recommendations

  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 1 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
9/27/2021CitigroupUpgradeNeutral ➝ Buy$11.00High
8/6/2021Royal Bank of CanadaLower Price TargetSector Perform$13.00 ➝ $6.00High
8/6/2021The Goldman Sachs GroupLower Price TargetSell$9.00 ➝ $8.00High
5/10/2021HC WainwrightReiterated RatingBuy$15.00High
8/10/2020CitigroupLower Price TargetNeutral$14.00 ➝ $12.00Medium
8/7/2020SVB LeerinkLower Price TargetMarket Perform$14.00 ➝ $10.00High
6/25/2020Bank of AmericaInitiated CoverageUnderperform$9.00High
5/20/2020Cantor FitzgeraldBoost Price TargetNeutral$14.00 ➝ $16.00High
5/15/2020SVB LeerinkReiterated RatingMarket PerformHigh
5/10/2020Royal Bank of CanadaReiterated RatingHold$13.00High
5/1/2020HC WainwrightReiterated RatingBuy$15.00High
4/20/2020Royal Bank of CanadaReiterated RatingHold$13.00High
2/28/2020CowenReiterated RatingHold$17.00High
2/26/2020HC WainwrightReiterated RatingBuy$15.00High
2/4/2020SVB LeerinkReiterated RatingMarket PerformHigh
1/27/2020Royal Bank of CanadaReiterated RatingHold$13.00Low
1/3/2020GuggenheimDowngradeBuy ➝ NeutralLow
12/12/2019HC WainwrightReiterated RatingBuy$15.00Medium
12/6/2019HC WainwrightInitiated CoverageBuy$15.00Medium
11/8/2019Cantor FitzgeraldLower Price TargetNeutral$20.00 ➝ $14.00High
11/7/2019BarclaysLower Price TargetUnderweight$9.00 ➝ $6.00High
11/7/2019Royal Bank of CanadaLower Price TargetSector Perform$13.00High
10/8/2019The Goldman Sachs GroupDowngradeNeutral ➝ Sell$24.00 ➝ $8.00High
8/12/2019CitigroupSet Price TargetHold$13.00High
8/12/2019JPMorgan Chase & Co.Reiterated RatingSell$13.00Medium
8/9/2019CowenReiterated RatingHold$25.00Low
8/9/2019BarclaysLower Price TargetUnderweight$21.00 ➝ $9.00High
7/5/2019CowenReiterated RatingHold$28.00High
6/5/2019CowenSet Price TargetHold$27.00Medium
5/29/2019The Goldman Sachs GroupLower Price TargetNeutral$29.00 ➝ $24.00Low
5/10/2019JPMorgan Chase & Co.Lower Price TargetUnderweight$27.00 ➝ $19.00High
5/10/2019CitigroupDowngradeBuy ➝ Neutral$24.00High
5/10/2019Cantor FitzgeraldDowngradeOverweight ➝ Neutral$57.00 ➝ $20.00High
4/1/2019JPMorgan Chase & Co.Reiterated RatingSellMedium
3/3/2019JPMorgan Chase & Co.Reiterated RatingSell$27.00Medium
3/1/2019CowenReiterated RatingHold$68.00Low
3/1/2019CitigroupBoost Price TargetBuy ➝ Buy$67.00 ➝ $70.00Medium
2/28/2019Cantor FitzgeraldReiterated RatingBuy$57.00High
1/17/2019SVB LeerinkInitiated CoverageMkt Perform ➝ Market Perform$21.00Low
1/3/2019GuggenheimDowngradeBuy ➝ NeutralHigh
12/18/2018Royal Bank of CanadaBoost Price TargetPositive ➝ Sector Perform$29.00Low
12/18/2018Cantor FitzgeraldBoost Price Target$55.00High
12/6/2018Royal Bank of CanadaBoost Price TargetSector Perform$26.00Low
11/19/2018The Goldman Sachs GroupUpgradeSell ➝ Neutral$36.00 ➝ $28.00Medium
11/2/2018Bank of AmericaDowngradeBuy ➝ UnderperformHigh
11/2/2018BarclaysDowngradeEqual Weight ➝ Underweight$72.00 ➝ $29.00High
11/2/2018CowenSet Price TargetHold$68.00High
11/2/2018JPMorgan Chase & Co.DowngradeNeutral ➝ Underweight$83.00 ➝ $23.00High
11/2/2018Cantor FitzgeraldReiterated RatingOverweight ➝ Buy$75.00 ➝ $50.00High
10/1/2018Cantor FitzgeraldInitiated CoverageOverweight ➝ Overweight$75.00Low
9/18/2018CitigroupLower Price TargetBuy$164.00 ➝ $151.00Medium
9/17/2018GuggenheimInitiated CoverageBuyHigh
9/17/2018The Goldman Sachs GroupInitiated CoverageSell ➝ Sell$42.00High
8/10/2018JPMorgan Chase & Co.Boost Price TargetOverweight ➝ Buy$80.00 ➝ $83.00High
8/10/2018CowenReiterated RatingHold$80.00High
6/28/2018CitigroupBoost Price TargetBuy ➝ Buy$146.00 ➝ $164.00Low
5/11/2018Stifel NicolausLower Price TargetBuy ➝ Buy$95.00 ➝ $87.00Medium
5/7/2018Credit Suisse GroupSet Price TargetBuy$106.00Medium
4/26/2018Credit Suisse GroupSet Price TargetBuy$106.00High
4/12/2018BarclaysDowngradeOverweight ➝ Equal Weight$90.00High
3/9/2018Stifel NicolausSet Price TargetBuy ➝ Buy$85.00 ➝ $95.00Low
3/2/2018Credit Suisse GroupSet Price TargetBuy$106.00High
3/2/2018BarclaysLower Price TargetOverweight ➝ Overweight$92.00 ➝ $90.00High
1/24/2018Bank of AmericaLower Price TargetBuy ➝ Buy$135.00 ➝ $115.00High
1/24/2018CitigroupLower Price TargetBuy ➝ Buy$164.00 ➝ $146.00High
1/24/2018Credit Suisse GroupLower Price TargetOutperform ➝ Outperform$147.00 ➝ $106.00High
1/24/2018Royal Bank of CanadaLower Price TargetSector Perform$77.00High
1/24/2018JPMorgan Chase & Co.Lower Price TargetOverweight ➝ Buy$138.00 ➝ $91.00High
1/24/2018CowenDowngradeOutperform ➝ Market Perform$123.00 ➝ $68.00High
1/22/2018Credit Suisse GroupSet Price TargetBuy$142.00 ➝ $147.00Low
1/15/2018Credit Suisse GroupSet Price TargetBuy$142.00High
1/3/2018CitigroupReiterated RatingBuy$164.00Low
11/10/2017Credit Suisse GroupBoost Price TargetOutperform$136.00 ➝ $142.00N/A
11/10/2017BarclaysReiterated RatingBuy$103.00 ➝ $122.00N/A
11/10/2017CitigroupBoost Price TargetBuy ➝ Buy$156.00 ➝ $164.00N/A
11/10/2017Royal Bank of CanadaLower Price TargetSector Perform$108.00 ➝ $92.00N/A
10/27/2017SVB LeerinkBoost Price TargetPositive ➝ Outperform$140.00N/A
10/9/2017Bank of AmericaReiterated RatingBuy$117.00 ➝ $135.00N/A
10/5/2017CitigroupReiterated RatingBuy$114.00 ➝ $156.00N/A
10/4/2017JPMorgan Chase & Co.Reiterated RatingBuy$131.00High
10/2/2017Stifel NicolausBoost Price TargetBuy$110.00 ➝ $130.00Low
9/27/2017Credit Suisse GroupReiterated RatingOutperform$136.00High
9/11/2017Credit Suisse GroupBoost Price TargetOutperform ➝ Outperform$118.00 ➝ $136.00Medium
9/6/2017BarclaysInitiated CoverageOverweight$103.00High
8/10/2017Stifel NicolausReiterated RatingBuy$118.00 ➝ $110.00High
8/9/2017JPMorgan Chase & Co.Set Price TargetBuy$105.00High
8/2/2017SVB LeerinkReiterated RatingOutperform$125.00Low
8/1/2017JPMorgan Chase & Co.Reiterated RatingBuyHigh
7/22/2017CowenReiterated RatingOutperform$91.00 ➝ $120.00Medium
7/21/2017Bank of AmericaReiterated RatingBuy$100.00 ➝ $117.00Low
7/19/2017SVB LeerinkReiterated RatingOutperform$115.00 ➝ $125.00Medium
7/18/2017JPMorgan Chase & Co.Reiterated RatingBuyMedium
7/18/2017CitigroupReiterated RatingBuy$114.00Medium
7/18/2017Stifel NicolausReiterated RatingBuy$105.00 ➝ $118.00Medium
7/18/2017Credit Suisse GroupReiterated RatingOutperform$90.00 ➝ $118.00High
7/17/2017Royal Bank of CanadaSet Price TargetHold$88.00Medium
7/10/2017Stifel NicolausReiterated RatingBuy$105.00Medium
7/10/2017SVB LeerinkReiterated RatingOutperform ➝ Outperform$115.00Medium
6/30/2017CitigroupReiterated RatingBuy$105.00Low
6/6/2017JPMorgan Chase & Co.Reiterated RatingOverweight$89.00Medium
6/6/2017Royal Bank of CanadaBoost Price TargetSector Perform ➝ Sector Perform$60.00 ➝ $88.00Low
6/5/2017Stifel NicolausReiterated RatingBuy$105.00Low
5/25/2017Credit Suisse GroupBoost Price TargetOutperform$58.00 ➝ $90.00Low
5/25/2017CowenUpgradeNeutral ➝ Outperform$91.00Low
5/25/2017Bank of AmericaBoost Price TargetBuy$72.00 ➝ $86.00Low
5/25/2017Royal Bank of CanadaBoost Price TargetSector Perform ➝ Sector Perform$40.00 ➝ $60.00Low
5/24/2017JPMorgan Chase & Co.Reiterated RatingOverweight$89.00Medium
5/22/2017Credit Suisse GroupSet Price TargetBuy$58.00High
5/22/2017CowenReiterated RatingMarket Perform ➝ Market PerformHigh
5/22/2017CitigroupReiterated RatingBuy$88.00High
5/22/2017Stifel NicolausReiterated RatingBuy$88.00High
5/10/2017Royal Bank of CanadaSet Price TargetHold$40.00Low
4/19/2017Stifel NicolausReiterated RatingBuy$88.00Low
4/18/2017Credit Suisse GroupReiterated RatingOutperform$58.00High
3/4/2017CitigroupReiterated RatingBuy$88.00N/A
3/3/2017Royal Bank of CanadaReiterated RatingSector Perform$57.00 ➝ $48.00N/A
3/2/2017Royal Bank of CanadaReiterated RatingSector Perform ➝ Sector Perform$48.00 ➝ $17.00N/A
3/2/2017Royal Bank of CanadaLower Price TargetSector Perform$48.00 ➝ $17.00N/A
(Data available from 1/22/2017 forward)

News Sentiment Rating

0.26 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
  • 1 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
  • 1 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
  • 0 very positive mentions
  • 3 positive mentions
  • 2 negative mentions
  • 2 very negative mentions
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
  • 2 very positive mentions
  • 5 positive mentions
  • 2 negative mentions
  • 0 very negative mentions

Current Sentiment

  • 2 very positive mentions
  • 5 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Puma Biotechnology logo
Puma Biotechnology, Inc. is a biopharmaceutical company. It acquires and develops innovative products for the treatment of various forms of cancer. The company focuses on in-licensing drug candidates that are undergoing or have already completed initial clinical testing for the treatment of cancer and then seek to further develop those drug candidates for commercial use. Puma Biotechnology was founded by Alan H. Auerbach on September 15, 2010 and is headquartered in Los Angeles, CA.
Read More

Today's Range

Now: $2.40
Low: $2.38
High: $2.55

50 Day Range

MA: $3.08
Low: $2.40
High: $3.68

52 Week Range

Now: $2.40
Low: $2.38
High: $14.14


1,059,564 shs

Average Volume

854,260 shs

Market Capitalization

$98.13 million

P/E Ratio


Dividend Yield




Frequently Asked Questions

What sell-side analysts currently cover shares of Puma Biotechnology?

The following equities research analysts have issued stock ratings on Puma Biotechnology in the last twelve months: Citigroup Inc., HC Wainwright, Royal Bank of Canada, The Goldman Sachs Group, Inc., and Zacks Investment Research.
View the latest analyst ratings for PBYI.

What is the current price target for Puma Biotechnology?

4 Wall Street analysts have set twelve-month price targets for Puma Biotechnology in the last year. Their average twelve-month price target is $10.00, suggesting a possible upside of 296.8%. HC Wainwright has the highest price target set, predicting PBYI will reach $15.00 in the next twelve months. Royal Bank of Canada has the lowest price target set, forecasting a price of $6.00 for Puma Biotechnology in the next year.
View the latest price targets for PBYI.

What is the current consensus analyst rating for Puma Biotechnology?

Puma Biotechnology currently has 1 sell rating, 1 hold rating and 2 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in PBYI, but not buy more shares or sell existing shares.
View the latest ratings for PBYI.

How do I contact Puma Biotechnology's investor relations team?

Puma Biotechnology's physical mailing address is 10880 WILSHIRE BOULEVARD SUITE 2150, LOS ANGELES CA, 90024. The biopharmaceutical company's listed phone number is (424) 248-6500 and its investor relations email address is [email protected] The official website for Puma Biotechnology is